HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
A phase 1/2 trial of HMPL-A580 in advanced solid tumours, run by Hutchmed, now recruiting.
Overview
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT07396584 by Hutchmed, with 186 participants planned, started 2026-03-04 and due to reach its primary completion in 2028-12-31. Interventions recorded: HMPL-A580.
Similar pages
not linked directly; found by shared links- TrialA Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Shares Hutchmed, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Shares Hutchmed, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.